DexCom Inc is expected to report Q3 2026 revenue of $1.32 billion and earnings per share of $0.66, with shares currently trading around $78.57 compared to a consensus price target of $96.19.
Investors are laser-focused on the adoption rate of the G7 15-day sensor and the sales trajectory of the Stelo over-the-counter biosensor following its recent U.S. launch.
Strong new-patient starts and expanded reimbursement coverage are expected to sustain top-line momentum, even as the company faces tougher year-over-year international comparisons. Management’s recent decision to raise full-year 2026 revenue guidance to $5.18-$5.25 billion has signaled confidence in continued market share gains within both the insulin-dependent and non-insulin-using patient segments.